Craig-Hallum raised the firm’s price target on Omnicell (OMCL) to $55 from $53 and keeps a Buy rating on the shares. Following the company’s beat and raise quarter, the firm believes there is still room for shares to run and wants investors to focus on how the company is positioning itself for the long term. Given the strong demand for demos, the company has increased their available units three times, which Craig-Hallum thinks will enable more customers to see/feel the benefits of Titan. Further, the firm believes continued innovation around OmniSphere and other services should drive enterprise-wide adoption of the company’s solutions in the coming periods.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
- Omnicell appoints Rick Couldry as SVP, chief pharmacy and clinical officer
- Omnicell price target raised to $70 from $60 at KeyBanc
- Analyst Reiterates Buy on Omnicell, Citing Once-in-a-Decade Product Cycle Momentum and Margin Strength; Price Target Maintained at $70
- Omnicell Earnings Call Shows Profits Surging, Outlook Raised
- Omnicell reports Q1 adjusted EPS 55c, consensus 33c
